the manufacturer shall submit to the Bureau the information outlined in subsection (a)(2)(A). (3) Revenue benchmark (A) In general Subject to subparagraph (B), for purposes of this subsection, the revenue benchmark is $5,000,000,000 in global revenue. (B) Update The Bureau may update the amount of the global benchmark over time. (d) General authority To review (1) In general The Bureau may at any time review the wholesale acquisition cost of a prescription drug to determine if such price is appropriate, including in response to a patient petition as described in section (2)(a)(3)(B)(ii). (2) Procedure The Bureau shall notify the manufacturer of a prescription drug it wishes to review pursuant to the authority under this subsection, and, within 45 days of receiving such a notification, the manufacturer shall submit to the Bureau information the Bureau determines necessary for its review. (e) Appropriate price determinations (1) Considerations In determining whether the wholesale acquisition cost or proposed wholesale acquisition cost of a prescription drug is appropriate, the Bureau shall consider the following: (A) The size of the affected patient population. (B) The therapeutic benefits of the prescription drug to patients. (C) The impact of the price on access to the prescription drug, including for patients who are uninsured, and the associated financial burden on patients that utilize such prescription drug. (D) The total annual Federal Government expenditures on the prescription drug and the budgetary impact of Federal health programs providing coverage of the prescription drug. (E) The risk-adjusted value of Federal Government subsidies and investments related to the prescription drug. (F) The costs associated with the development of the prescription drug. (G) The number of similarly effective prescription drugs or alternative treatment regimens for each approved use of such prescription drug. (H) Whether the prescription drug provided a significant improvement in health outcomes, compared to other